Thermo Fisher Scientific, Inc.

As of October 24, 2025, Thermo Fisher Scientific, Inc. shows a bullish technical trend supported by positive moving averages and Bollinger Bands, despite some short-term weakness indicated by the RSI.

As of October 24, 2025, Thermo Fisher Scientific, Inc. shows a bullish technical trend supported by positive moving averages and Bollinger Bands, despite a bearish weekly RSI, while outperforming the S&P 500 in the short term but underperforming over longer periods.

As of October 17, 2025, Thermo Fisher Scientific, Inc. is fairly valued with a P/E ratio of 26 and an EV to EBITDA of 18.39, having recently outperformed the S&P 500 over the past week but lagging behind in one-year returns.

As of October 17, 2025, Thermo Fisher Scientific, Inc. is fairly valued with a P/E ratio of 26, an EV to EBITDA of 18.39, and a Price to Book Value of 3.44, but has underperformed over the past year with a return of -10.07% compared to the S&P 500's 14.08%.

As of October 17, 2025, Thermo Fisher Scientific, Inc. is fairly valued with a P/E ratio of 26, recent stock performance shows a 2.69% return over the past week but a -10.07% return over the past year, indicating short-term strength but longer-term caution compared to the S&P 500.

As of October 3, 2025, Thermo Fisher Scientific, Inc. shows a mildly bullish technical trend, supported by positive moving averages and Bollinger Bands, despite some bearish signals in the MACD and RSI, with recent performance outperforming the S&P 500 over the past week and month but underperforming over the past year.

As of October 3, 2025, Thermo Fisher Scientific, Inc. shows a mildly bullish trend driven by short-term indicators, despite mixed signals from MACD and RSI, and has outperformed the S&P 500 recently while underperforming over the longer term.

As of October 3, 2025, Thermo Fisher Scientific, Inc. shows a mildly bullish trend due to positive indicators like a bullish MACD and Bollinger Bands, despite mixed signals from monthly MACD and KST, and underperformance over longer periods compared to the S&P 500.

As of July 24, 2025, Thermo Fisher Scientific, Inc. has shifted to a mildly bearish trend, influenced by daily moving averages and Dow Theory signals, despite bullish weekly indicators and a year-to-date return of -7.52% compared to the S&P 500's 12.22%.

As of July 23, 2025, Thermo Fisher Scientific, Inc. is fairly valued with a P/E ratio of 26, but has underperformed the S&P 500 with year-to-date and one-year returns of -7.52% and -21.15%, respectively, suggesting caution for potential investors.

As of April 23, 2025, Thermo Fisher Scientific, Inc. is considered undervalued with an attractive valuation grade, a P/E ratio of 26, and a PEG ratio of 4.99, despite underperforming the S&P 500 over the past year.

As of March 10, 2025, Thermo Fisher Scientific, Inc. shows a bearish trend with moderate strength, indicated by bearish signals from MACD, moving averages, KST, and Bollinger Bands, despite a bullish weekly RSI.

As of March 2022, the management team of Thermo Fisher Scientific, Inc. includes Marc Casper (Chairman, President, and CEO), Thomas Lynch (Lead Independent Director), R. Alexandra Keith, Nelson Chai, C. Martin Harris, and Tyler Jacks (all Independent Directors). They are responsible for guiding the company's strategic direction and operations.

Thermo Fisher Scientific, Inc. develops and sells products in the Pharmaceuticals & Biotechnology industry, with recent net sales of $10.36 billion and a market cap of $164.77 billion. Key metrics include a P/E ratio of 26.00 and a dividend yield of 0.38%.